SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-24-002655
Filing Date
2024-01-08
Accepted
2024-01-08 06:03:45
Documents
13
Period of Report
2024-01-07
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K rare-20240107.htm   iXBRL 8-K 43040
2 EX-99.1 rare-ex99_1.htm EX-99.1 35116
3 GRAPHIC img45776771_0.jpg GRAPHIC 375412
4 GRAPHIC img45776771_1.jpg GRAPHIC 14202
  Complete submission text file 0000950170-24-002655.txt   732186

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT rare-20240107.xsd EX-101.SCH 23897
7 EXTRACTED XBRL INSTANCE DOCUMENT rare-20240107_htm.xml XML 4516
Mailing Address 60 LEVERONI COURT NOVATO CA 94949
Business Address 60 LEVERONI COURT NOVATO CA 94949 415-483-8800
Ultragenyx Pharmaceutical Inc. (Filer) CIK: 0001515673 (see all company filings)

IRS No.: 272546083 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36276 | Film No.: 24518174
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)